Orasure Tech Inc (OSUR) Stock Price, Quote & News

Company Profile

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVI...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 610 882 1820

Website: www.orasure.com

Address:

220 East First Street, Bethlehem, United States

focafoca99 Apr. 17 at 8:01 PM

$OSUR added John Bertrand to its board, agreed with Altai Capital to pursue board declassification, and got the activist to withdraw director nominations.

0 · Reply

briefingcom Apr. 17 at 12:42 PM

$OSUR: OraSure appoints director and reaches agreement with activist investor https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260417044623OSUR&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

focafoca99 Mar. 31 at 2:07 AM

$OSUR is filing is a defense deck against Altai Capital, with management trying to control the narrative before the board fight goes any further.

0 · Reply

Estimize Mar. 25 at 1:03 PM

Wall St is expecting -0.16 EPS for $OSUR Q1 [Reporting 05/13 AMC] http://www.estimize.com/intro/osur?chart=historical&metric_name=eps&utm_c

0 · Reply

AlertsAndNews Mar. 24 at 2:51 AM

$OSUR Multiple insider buys here. Form 4s Kenneth J. McGrath (Chief Financial Officer) purchased 32,300 shares at an average price of $2.93 (Form 4). Carrie Eglinton Manner (Director, President & CEO) purchased 32,300 shares at an average price of $2.93 (Form 4).

0 · Reply

CEOBuysDisclosures Mar. 24 at 1:25 AM

$OSUR CEO purchased 32,300 shares at $2.93 for a total of $94,597. EGLINTON MANNER CARRIE now owns 2,190,874 shares. https://ceo-buys.com

0 · Reply

Investor6 Mar. 18 at 5:12 PM

$OSUR about the same happened with BARK, the result was the activists with Marcus Lemonis to offer $1.10 (current sp $0.81) a couple of months after their letter. So, keep an eye to any signs that a buyout proposal could occur.

1 · Reply

focafoca99 Mar. 17 at 9:44 PM

$OSUR is clearly responding after that Altai Capital letter

0 · Reply

AStrokeOfLuck Mar. 17 at 9:30 PM

$OSUR

0 · Reply

Shlobby Mar. 14 at 6:44 PM

$OSUR interesting setup over 3.30

0 · Reply

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

Mar 17, 2026, 4:52 PM EDT - 4 weeks ago

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

Mar 17, 2026, 9:15 AM EDT - 4 weeks ago

Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

Mar 17, 2026, 8:02 AM EDT - 4 weeks ago

Exclusive: Altai Capital presses OraSure to sell and give it board seats, letter says

Feb 10, 2026, 8:05 AM EST - 2 months ago

OraSure to Launch OraQuick™ HIV Self-Test in Canada

Feb 9, 2026, 4:15 PM EST - 2 months ago

OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th

Jan 15, 2026, 1:00 PM EST - 3 months ago

OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital

Jan 15, 2026, 8:30 AM EST - 3 months ago

Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors

Dec 17, 2025, 1:23 PM EST - 4 months ago

OraSure Technologies Issues Statement Regarding Altai Capital's Intent to Nominate Director Candidates

Dec 17, 2025, 8:00 AM EST - 4 months ago

Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors

Oct 29, 2025, 7:30 AM EDT - 6 months ago

OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th

Oct 28, 2025, 4:22 PM EDT - 6 months ago

OraSure Technologies Appoints Steven K. Boyd to its Board of Directors

Sep 9, 2025, 6:19 AM EDT - 7 months ago

Exclusive: Altai Capital lays groundwork for board fight at OraSure Technologies, sources say

Aug 25, 2025, 12:12 PM EDT - 8 months ago

Exclusive: Healthcare entrepreneur's letter threatens 'adversarial path' after OraSure Tech rebuffs bid

Aug 4, 2025, 7:05 AM EDT - 9 months ago

OraSure Appoints Anne Messing as Chief Commercial Officer

Jul 21, 2025, 4:05 PM EDT - 9 months ago

OraSure to Announce Second Quarter 2025 Financial Results and Host Earnings Call on August 5th

Jul 14, 2025, 12:03 PM EDT - 9 months ago

OraSure Technologies received takeover bid from industry entrepreneur, sources say

Jul 10, 2025, 7:05 AM EDT - 10 months ago

OraSure Launches Novel Blood Collection Device for Proteomic Research

Apr 23, 2025, 4:05 PM EDT - 1 year ago

OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th

Mar 24, 2025, 7:30 AM EDT - 1 year ago

OraSure Announces $40 Million Stock Repurchase Program

Feb 14, 2025, 8:45 AM EST - 1 year ago

OraSure to Announce Fourth Quarter 2024 Financial Results and Host Earnings Call on February 25th

Jan 13, 2025, 8:00 AM EST - 1 year ago

NOWDiagnostics Responds with Countersuit Against Frivolous OraSure Claims

Jan 7, 2025, 4:05 PM EST - 1 year ago

OraSure to Present at the J.P Morgan Healthcare Conference

Jan 7, 2025, 8:50 AM EST - 1 year ago

CORRECTION - OraQuick® HIV Self-Test Now Approved for Use in Adolescents

Jan 7, 2025, 7:05 AM EST - 1 year ago

OraQuick® HIV Self-Test Now Approved for Use in Adolescents

Dec 19, 2024, 4:02 PM EST - 1 year ago

OraSure Technologies Acquires Sherlock Biosciences

Dec 2, 2024, 7:05 AM EST - 1 year ago

OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test

Nov 18, 2024, 4:05 PM EST - 1 year ago

OraSure to Participate in Upcoming Investor Conference

Nov 6, 2024, 4:05 PM EST - 1 year ago

OraSure Reports Q3 '24 Revenue of $39.9 Million

Oct 22, 2024, 4:05 PM EDT - 1 year ago

OraSure to Announce Third Quarter 2024 Financial Results and Host Earnings Call on November 6th

Oct 4, 2024, 4:03 PM EDT - 1 year ago

Neuberger Berman Group LLC Expands Stake in OraSure Technologies Inc

Sep 9, 2024, 7:05 AM EDT - 1 year ago

OraSure Technologies Elects Jack Kenny to the Board of Directors

Jul 22, 2024, 4:05 PM EDT - 1 year ago

OraSure to Announce Second Quarter 2024 Financial Results and Host Earnings Call on August 6th

Jun 27, 2024, 7:05 AM EDT - 1 year ago

OraSure Technologies Supports National HIV Testing Day

Apr 22, 2024, 8:00 AM EDT - 2 years ago

OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th

Mar 21, 2024, 8:31 AM EDT - 2 years ago

NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board

Feb 27, 2024, 4:05 PM EST - 2 years ago

OraSure Reports Q4 ‘23 Revenue of $75.9 Million

Feb 13, 2024, 4:05 PM EST - 2 years ago

OraSure to Announce Fourth Quarter 2023 Financial Results and Host Earnings Call on February 27th

Jan 4, 2024, 7:05 AM EST - 2 years ago

OraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests in Sapphiros, a Next-Generation Consumer Diagnostics Company

Nov 13, 2023, 4:15 PM EST - 2 years ago

OraSure to Participate in Upcoming Investor Conferences

Oct 23, 2023, 4:05 PM EDT - 2 years ago

OraSure to Announce Third Quarter 2023 Financial Results and Host Earnings Call on November 7th

Aug 3, 2023, 4:05 PM EDT - 2 years ago

OraSure Reports Q2 ‘23 Revenue of $85.4 Million; Core Revenue Grows 3% Year-over-Year

Jul 20, 2023, 7:05 AM EDT - 2 years ago

OraSure Technologies Elects Robert McMahon to the Board of Directors

Jun 13, 2023, 4:05 PM EDT - 3 years ago

Study Concludes Self-Sampling Using Colli-Pee® Device for HPV Screening Is Both Cost Effective and Could Improve Patient Access

May 10, 2023, 4:05 PM EDT - 3 years ago

OraSure Reports 1Q23 Record Revenue of $155.0 Million; Announces New Collaborations as Company Increasingly Focuses on Core Growth

May 3, 2023, 7:05 AM EDT - 3 years ago

2023 First Quarter Earnings Conference Call Wednesday, May 10, 2023, 5:00 p.m. ET

Feb 14, 2023, 4:05 PM EST - 3 years ago

OraSure Reports 4Q22 Record Revenue of $123.1 Million Growing 94% Year-Over-Year; Positions for Longer-Term Growth and Profitability

Feb 7, 2023, 7:05 AM EST - 3 years ago

2022 Fourth Quarter Earnings Conference Call Tuesday, February 14, 2023, 5:00 p.m. ET

Dec 1, 2022, 7:05 AM EST - 3 years ago

OraSure Technologies Continues its Dedication to Ending the HIV Epidemic

Nov 14, 2022, 7:05 AM EST - 3 years ago

OraSure Technologies to Present at Stephens Annual Investment Conference

focafoca99 Apr. 17 at 8:01 PM

$OSUR added John Bertrand to its board, agreed with Altai Capital to pursue board declassification, and got the activist to withdraw director nominations.

0 · Reply

briefingcom Apr. 17 at 12:42 PM

0 · Reply

focafoca99 Mar. 31 at 2:07 AM

$OSUR is filing is a defense deck against Altai Capital, with management trying to control the narrative before the board fight goes any further.

0 · Reply

Estimize Mar. 25 at 1:03 PM

Wall St is expecting -0.16 EPS for $OSUR Q1 [Reporting 05/13 AMC] http://www.estimize.com/intro/osur?chart=historical&metric_name=eps&utm_c

0 · Reply

AlertsAndNews Mar. 24 at 2:51 AM

0 · Reply

CEOBuysDisclosures Mar. 24 at 1:25 AM

$OSUR CEO purchased 32,300 shares at $2.93 for a total of $94,597. EGLINTON MANNER CARRIE now owns 2,190,874 shares. https://ceo-buys.com

0 · Reply

Investor6 Mar. 18 at 5:12 PM

1 · Reply

focafoca99 Mar. 17 at 9:44 PM

$OSUR is clearly responding after that Altai Capital letter

0 · Reply

AStrokeOfLuck Mar. 17 at 9:30 PM

$OSUR

0 · Reply

Shlobby Mar. 14 at 6:44 PM

$OSUR interesting setup over 3.30

0 · Reply

OfficialStocktwitsUser Mar. 14 at 3:15 AM

$OSUR RSI: 58.87, MACD: 0.0916 Vol: 0.16, MA20: 2.96, MA50: 2.80 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Alien1980 Mar. 6 at 9:30 PM

$SWBI on the open swing traded all day in this saturated market. 12.97-13.9 🥇 $OSUR 2.95-3.15 ✔ $S 1 week swang from 13 🛸 USA allegiance to Israel will cost so many american lives in the months to come. This will be this generations Vietnam. Stay patient, wait for market to form STRUCTURE before entering any trades. Odds are stacked against you to lose money 👽👽

0 · Reply

StockScanners Feb. 28 at 7:30 PM

$OSUR reached 3.22

0 · Reply

StockScanners Feb. 27 at 4:30 AM

$OSUR keep watch if this holds above 3

0 · Reply

StocktwitsEarnings Feb. 25 at 9:22 PM

$OSUR Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.27 down -92.86% YoY • Reported revenue of $26.76M down -28.53% YoY • OraSure Technologies is guiding to Q1 2026 total revenues of $26M to $29M, which includes a negligible amount of COVID-19 testing revenues, indicating a challenging funding environment.

0 · Reply

SignalRaider Feb. 18 at 9:16 AM

$OSUR Diagnostics name sensitive to reimbursement and testing demand cycles.

0 · Reply

OfficialStocktwitsUser Feb. 14 at 12:18 AM

$OSUR RSI: 52.63, MACD: 0.0532 Vol: 0.08, MA20: 2.76, MA50: 2.61 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Benz95 Feb. 10 at 1:12 PM

$OSUR https://www.stocktitan.net/news/OSUR/ora-sure-to-launch-ora-quick-tm-hiv-self-test-in-g0eig7kwlgnk.html

0 · Reply

OfficialStocktwitsUser Jan. 20 at 12:29 PM

$OSUR RSI: 67.09, MACD: 0.0596 Vol: 0.12, MA20: 2.52, MA50: 2.45 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ZacksResearch Jan. 6 at 5:43 PM

$OSUR makes a regulatory move that could reshape its growth path 👀 OraSure just filed FDA applications for two at-home STI tests — a molecular self-test and the Colli-Pee device — pushing deeper into decentralized diagnostics, with shares up 3.8% on the news. Is this a long-term growth inflection? Full details here 👉 https://www.zacks.com/stock/news/2812722/orasure-files-for-fda-review-of-molecular-self-test-colli-pee-device?cid=sm-stocktwits-2-2812722-teaser-27612&ADID=SYND_STOCKTWITS_TWEET_2_2812722_TEASER_27612

0 · Reply

ZacksResearch Jan. 6 at 4:43 PM

$OSUR gains 3.8% on FDA submission news — a turning point? 🚀 OraSure Technologies filed for FDA approval on two at-home STI tests, aiming to decentralize diagnostics and tap into the $1.5B CT/NG testing market, which is currently dominated by centralized labs. Long-term, this could bolster recurring revenues and expand its market reach. Discover the growth potential here 👉 https://www.zacks.com/stock/news/2812722/orasure-files-for-fda-review-of-molecular-self-test-colli-pee-device?cid=sm-stocktwits-2-2812722-body-27595&ADID=SYND_STOCKTWITS_TWEET_2_2812722_BODY_27595

0 · Reply

DARKP00L Jan. 5 at 1:22 PM

$OSUR 08:04 on Jan. 05 2026 OraSure Submits Two Separate Applications At 2025 End To FDA For Clearance Of Rapid Molecular Self-Test For CT/NG As Well As Colli-Pee At-Home Urine Collection Device For STIs #tradeideas

1 · Reply

Market Cap	218.44M
Revenue (ttm)	115.02M
Net Income (ttm)	-68.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-59.75%
Debt to Equity Ratio	0.00

Volume	305,900
Avg Vol	476,484
Day's Range	N/A - N/A
Shares Out	69.13M
Stochastic %K	69%
Beta	0.85
Analysts	Hold
Price Target	$4.00